JPWO2020157577A5 - - Google Patents
Download PDFInfo
- Publication number
- JPWO2020157577A5 JPWO2020157577A5 JP2021544351A JP2021544351A JPWO2020157577A5 JP WO2020157577 A5 JPWO2020157577 A5 JP WO2020157577A5 JP 2021544351 A JP2021544351 A JP 2021544351A JP 2021544351 A JP2021544351 A JP 2021544351A JP WO2020157577 A5 JPWO2020157577 A5 JP WO2020157577A5
- Authority
- JP
- Japan
- Prior art keywords
- medicament
- biphenyl
- chloro
- amino
- diazaspiro
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 239000002552 dosage form Substances 0.000 claims description 10
- 206010064911 Pulmonary arterial hypertension Diseases 0.000 claims description 8
- 235000010290 biphenyl Nutrition 0.000 claims description 4
- ZUOUZKKEUPVFJK-UHFFFAOYSA-N diphenyl Chemical group C1=CC=CC=C1C1=CC=CC=C1 ZUOUZKKEUPVFJK-UHFFFAOYSA-N 0.000 claims description 4
- 239000000546 pharmaceutic aid Substances 0.000 claims description 4
- QZAYGJVTTNCVMB-UHFFFAOYSA-N serotonin Chemical compound C1=C(O)C=C2C(CCN)=CNC2=C1 QZAYGJVTTNCVMB-UHFFFAOYSA-N 0.000 claims description 4
- DUUGKQCEGZLZNO-UHFFFAOYSA-N 5-hydroxyindoleacetic acid Chemical compound C1=C(O)C=C2C(CC(=O)O)=CNC2=C1 DUUGKQCEGZLZNO-UHFFFAOYSA-N 0.000 claims description 3
- 230000035533 AUC Effects 0.000 claims description 3
- 230000000977 initiatory Effects 0.000 claims description 3
- TZSZZENYCISATO-WIOPSUGQSA-N rodatristat Chemical compound CCOC(=O)[C@@H]1CC2(CN1)CCN(CC2)c1cc(O[C@H](c2ccc(Cl)cc2-c2ccccc2)C(F)(F)F)nc(N)n1 TZSZZENYCISATO-WIOPSUGQSA-N 0.000 claims description 3
- 230000002485 urinary Effects 0.000 claims description 3
- 206010020772 Hypertension Diseases 0.000 claims description 2
- 210000004072 Lung Anatomy 0.000 claims description 2
- 229940076279 Serotonin Drugs 0.000 claims description 2
- 230000015572 biosynthetic process Effects 0.000 claims description 2
- 239000006186 oral dosage form Substances 0.000 claims description 2
- 230000002685 pulmonary Effects 0.000 claims description 2
- 239000003814 drug Substances 0.000 claims 30
- BGMBESSESNFHQD-UHFFFAOYSA-M [O-]C(=O)C1CC2(CN1)CCNCC2 Chemical compound [O-]C(=O)C1CC2(CN1)CCNCC2 BGMBESSESNFHQD-UHFFFAOYSA-M 0.000 claims 1
- 230000037348 biosynthesis Effects 0.000 claims 1
- 239000004305 biphenyl Substances 0.000 claims 1
- 229940079593 drugs Drugs 0.000 claims 1
- 125000006005 fluoroethoxy group Chemical group 0.000 claims 1
- 125000003652 trifluoroethoxy group Chemical group FC(CO*)(F)F 0.000 claims 1
- 230000004048 modification Effects 0.000 description 2
- 238000006011 modification reaction Methods 0.000 description 2
- YRCGAHTZOXPQPR-UHFFFAOYSA-N 2-ethylnonanoic acid Chemical compound CCCCCCCC(CC)C(O)=O YRCGAHTZOXPQPR-UHFFFAOYSA-N 0.000 description 1
- 230000003247 decreasing Effects 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 230000002194 synthesizing Effects 0.000 description 1
Description
前述の説明は、本発明の例示に過ぎない。本発明から逸脱することなく、様々な代替案や修正案を考案することが可能である。したがって、本発明は、添付の特許請求の範囲に含まれるすべての代替品、変更、および差異を包含することを意図している。
例えば、本発明は、以下の項目を提供する。
(項目1)
2つの個別の剤形を含み、各剤形がそれぞれ、約600mg~約800mgの量の(S)-エチル8-(2-アミノ-6-((R)-1-(5-クロロ-[1,1’-ビフェニル]-2-イル)-2,2,2-トリフルオロエトキシ)ピリミジン-4-イル)-2,8-ジアザスピロ[4.5]デカン-3-カルボキシレートを含む、肺動脈性肺高血圧症を治療するための1日投与レジメン。
(項目2)
剤形がそれぞれRVT-1201を含み、その中の(S)-エチル8-(2-アミノ-6-((R)-1-(5-クロロ-[1,1’-ビフェニル]-2-イル)-2,2,2-トリフルオロエトキシ)ピリミジン-4-イル)-2,8-ジアザスピロ[4.5]デカン-3-カルボキシレートが実質的に図1に示されている、項目1の1日投与レジメン。
(項目3)
剤形が経口剤であることを特徴とする、項目1または2の1日投与レジメン。
(項目4)
それぞれの剤形が、薬学的に許容される賦形剤の量をさらに含むことを特徴とする、項目1から3のいずれかの1日投与レジメン。
(項目5)
(S)-エチル8-(2-アミノ-6-((R)-1-(5-クロロ-[1,1’-ビフェニル]-2-イル)-2,2,2-トリフルオロエトキシ)ピリミジン-4-イル)-2,8-ジアザスピロ[4.5]デカン-3-カルボキシレートを1200mgから1600mgの量で含むことを特徴とする、肺動脈性肺高血圧症を治療するための1日投与レジメン。
(項目6)
(S)-エチル8-(2-アミノ-6-((R)-1-(5-クロロ-[1,1’-ビフェニル]-2-イル)-2,2,2-トリフルオロエトキシ)ピリミジン-4-イル)-2,8-ジアザスピロ[4.5]デカン-3-カルボキシレートが実質的に項目1に示されている通りであることを特徴とする、項目5の1日投与レジメン。
(項目7)
投与量がさらに薬学的に許容される賦形剤を含むことを特徴とする、項目5または6の1日投与レジメン。
(項目8)
1日あたり1200mgから1600mgの量の(S)-エチル8-(2-アミノ-6-((R)-1-(5-クロロ-[1,1’-ビフェニル]-2-イル)-2,2,2-トリフルオロエトキシ)ピリミジン-4-イル)-2,8-ジアザスピロ[4.5]デカン-3-カルボキシレートをヒト患者に投与することを含む、肺動脈性肺高血圧症を治療する方法。
(項目9)
(S)-エチル8-(2-アミノ-6-((R)-1-(5-クロロ-[1,1’-ビフェニル]-2-イル)-2,2,2-トリフルオロエトキシ)ピリミジン-4-イル)-2,8-ジアザスピロ[4.5]デカン-3-カルボキシレートが実質的に図1に示されている通りであることを特徴とする、項目8の方法。
(項目10)
量を経口的に投与する、項目8または9の方法。
(項目11)
600mgから800mgをBIDで投与する、項目8から11のいずれかの方法。
(項目12)
1日あたり約800mgから約1600mgの量の(S)-エチル8-(2-アミノ-6-((R)-1-(5-クロロ-[1,1’-ビフェニル]-2-イル)-2,2,2-トリフルオロエトキシ)ピリミジン-4-イル)-2,8-ジアザスピロ[4.5]デカン-3-カルボキシレートをヒト患者に投与することで、治療開始後14日以内にセロトニン生合成レベルを少なくとも50%低下させる方法。
(項目13)
(S)-エチル8-(2-アミノ-6-((R)-1-(5-クロロ-[1,1’-ビフェニル]-2-イル)-2,2,2-トリフルオロエトキシ)ピリミジン-4-イル)-2,8-ジアザスピロ[4.5]デカン-3-カルボキシレートが実質的に図1に示されている通りであることを特徴とする、項目12の方法。
(項目14)
量を経口的に投与する、項目12または13の方法。
(項目15)
約400mgから約800mgをBIDで投与する、項目12から14のいずれかの方法。
(項目16)
約400mgBID、600mgBID、および800mg BIDからなる群から選択される投与量を投与される、項目12の方法。
(項目17)
(S)-エチル8-(2-アミノ-6-((R)-1-(5-クロロ-[1,1’-ビフェニル]-2-イル)-2,2,2-トリフルオロエトキシ)ピリミジン-4-イル)-2,8-ジアザスピロ[4.5]デカン-3-カルボキシレートの有効量をヒト患者に毎日投与し、投与後14日以内に(S)-8-(2-アミノ-6-((R)-1-(5-クロロ-[1,1’-ビフェニル]-2-イル)-2,2,2-トリフルオロエトキシ)ピリミジン-4-イル)-2,8-ジアザスピロ[4.5]デカン-3-カルボン酸がAUC
0-tau
≧2530ng.hr/mLとなる方法。
(項目18)
投与量が1日あたり約800mgから約1600mgである、項目17の方法。
(項目19)
約400mgから約800mgをBIDで投与する、項目18の方法。
(項目19)
(S)-エチル8-(2-アミノ-6-((R)-1-(5-クロロ-[1,1’-ビフェニル]-2-イル)-2,2,2-トリフルオロエトキシ)ピリミジン-4-イル)-2,8-ジアザスピロ[4.5]デカン-3-カルボキシレートの有効量をヒト患者に毎日投与し、投与後14日以内に尿中5-HIAAの50%を上回る減少を達成する方法。
(項目20)
投与量が1日あたり約800mgから約1600mgである、項目19の方法。
(項目21)
投与量が約400mgから約800mgをBIDで投与する、項目20の方法。
(項目22)
投与開始後14日以内に(S)-8-(2-アミノ-6-((R)-1-(5-クロロ-[1,1’-ビフェニル]-2-イル)-2,2,2-トリフルオロエトキシ)ピリミジン-4-イル)-2,8-ジアザスピロ[4.5]デカン-3-カルボン酸のAUC
0-tau
が≧2530ng.hr/mLとなるのに十分な量の(S)-エチル8-(2-アミノ-6-((R)-1-(5-クロロ-[1,1’-ビフェニル]-2-イル)-2,2,2-トリフルオロエトキシ)ピリミジン-4-イル)-2,8-ジアザスピロ[4.5]デカン-3-カルボキシレートを、必要とするヒト患者に毎日投与する、肺動脈性肺高血圧症を治療する方法。
(項目23)
必要とするヒト患者に有効量の(S)-エチル8-(2-アミノ-6-((R)-1-(5-クロロ-[1,1’-ビフェニル]-2-イル)-2,2,2-トリフルオロエトキシ)ピリミジン-4-イル)-2,8-ジアザスピロ[4.5]デカン-3-カルボキシレートを毎日投与し、投与開始後14日以内に尿中5-HIAAを50%を上回る減少をさせるのに有効な肺動脈性肺高血圧症の治療方法。
The foregoing description is merely exemplary of the invention. Various alternatives and modifications can be devised without departing from the invention. Accordingly, the present invention is intended to embrace all alternatives, modifications and variations that fall within the scope of the appended claims.
For example, the present invention provides the following items.
(Item 1)
comprising two separate dosage forms, each dosage form containing (S)-ethyl 8-(2-amino-6-((R)-1-(5-chloro-[ pulmonary arterial lung containing 1,1'-biphenyl]-2-yl)-2,2,2-trifluoroethoxy)pyrimidin-4-yl)-2,8-diazaspiro[4.5]decane-3-carboxylate A daily dosing regimen for treating hypertension.
(Item 2)
Each dosage form comprises RVT-1201, in which (S)-ethyl 8-(2-amino-6-((R)-1-(5-chloro-[1,1'-biphenyl]-2- yl)-2,2,2-trifluoroethoxy)pyrimidin-4-yl)-2,8-diazaspiro[4.5]decane-3-carboxylate is substantially as shown in FIG. daily dosing regimen.
(Item 3)
The daily administration regimen of item 1 or 2, characterized in that the dosage form is an oral dosage form.
(Item 4)
4. The daily dosage regimen of any of items 1-3, wherein each dosage form further comprises an amount of a pharmaceutically acceptable excipient.
(Item 5)
(S)-ethyl 8-(2-amino-6-((R)-1-(5-chloro-[1,1'-biphenyl]-2-yl)-2,2,2-trifluoroethoxy) A daily dosage regimen for treating pulmonary arterial hypertension, characterized in that it comprises pyrimidin-4-yl)-2,8-diazaspiro[4.5]decane-3-carboxylate in an amount of 1200 mg to 1600 mg.
(Item 6)
(S)-ethyl 8-(2-amino-6-((R)-1-(5-chloro-[1,1'-biphenyl]-2-yl)-2,2,2-trifluoroethoxy) The daily dosage regimen of item 5, wherein the pyrimidin-4-yl)-2,8-diazaspiro[4.5]decane-3-carboxylate is substantially as set forth in item 1.
(Item 7)
The daily dosing regimen of items 5 or 6, characterized in that the dose further comprises a pharmaceutically acceptable excipient.
(Item 8)
(S)-ethyl 8-(2-amino-6-((R)-1-(5-chloro-[1,1'-biphenyl]-2-yl)-2 in an amount of 1200 mg to 1600 mg per day A method of treating pulmonary arterial hypertension comprising administering ,2,2-trifluoroethoxy)pyrimidin-4-yl)-2,8-diazaspiro[4.5]decane-3-carboxylate to a human patient.
(Item 9)
(S)-ethyl 8-(2-amino-6-((R)-1-(5-chloro-[1,1'-biphenyl]-2-yl)-2,2,2-trifluoroethoxy) 9. The method of item 8, wherein the pyrimidin-4-yl)-2,8-diazaspiro[4.5]decane-3-carboxylate is substantially as shown in FIG.
(Item 10)
The method of item 8 or 9, wherein the amount is administered orally.
(Item 11)
Any method of items 8-11, administering 600 mg to 800 mg BID.
(Item 12)
(S)-ethyl 8-(2-amino-6-((R)-1-(5-chloro-[1,1'-biphenyl]-2-yl) in an amount of about 800 mg to about 1600 mg per day Administration of -2,2,2-trifluoroethoxy)pyrimidin-4-yl)-2,8-diazaspiro[4.5]decane-3-carboxylate to human patients resulted in increased serotonin production within 14 days after initiation of treatment. How to reduce synthesis levels by at least 50%.
(Item 13)
(S)-ethyl 8-(2-amino-6-((R)-1-(5-chloro-[1,1'-biphenyl]-2-yl)-2,2,2-trifluoroethoxy) 13. The method of item 12, wherein the pyrimidin-4-yl)-2,8-diazaspiro[4.5]decane-3-carboxylate is substantially as shown in FIG.
(Item 14)
14. The method of items 12 or 13, wherein the amount is administered orally.
(Item 15)
The method of any of items 12-14, wherein about 400 mg to about 800 mg is administered BID.
(Item 16)
13. The method of item 12, wherein a dose selected from the group consisting of about 400 mg BID, 600 mg BID, and 800 mg BID is administered.
(Item 17)
(S)-ethyl 8-(2-amino-6-((R)-1-(5-chloro-[1,1'-biphenyl]-2-yl)-2,2,2-trifluoroethoxy) An effective dose of pyrimidin-4-yl)-2,8-diazaspiro[4.5]decane-3-carboxylate was administered daily to human patients, and (S)-8-(2-amino-6 -((R)-1-(5-chloro-[1,1'-biphenyl]-2-yl)-2,2,2-trifluoroethoxy)pyrimidin-4-yl)-2,8-diazaspiro[ 4.5] A method in which decane-3-carboxylic acid achieves AUC 0-tau ≧2530 ng.hr/mL.
(Item 18)
18. The method of item 17, wherein the dosage is from about 800 mg to about 1600 mg per day.
(Item 19)
19. The method of item 18, wherein about 400 mg to about 800 mg is administered BID.
(Item 19)
(S)-ethyl 8-(2-amino-6-((R)-1-(5-chloro-[1,1'-biphenyl]-2-yl)-2,2,2-trifluoroethoxy) Daily administration of an effective amount of pyrimidin-4-yl)-2,8-diazaspiro[4.5]decane-3-carboxylate to human patients resulted in a greater than 50% reduction in urinary 5-HIAA within 14 days of administration. how to achieve.
(Item 20)
19. The method of item 19, wherein the dosage is from about 800 mg to about 1600 mg per day.
(Item 21)
21. The method of item 20, wherein the dosage is from about 400 mg to about 800 mg BID.
(Item 22)
(S)-8-(2-amino-6-((R)-1-(5-chloro-[1,1'-biphenyl]-2-yl)-2,2, A sufficient amount of (S) to achieve an AUC 0-tau of 2-trifluoroethoxy)pyrimidin-4-yl)-2,8-diazaspiro[4.5]decane-3-carboxylic acid ≥2530 ng.hr/mL -ethyl 8-(2-amino-6-((R)-1-(5-chloro-[1,1'-biphenyl]-2-yl)-2,2,2-trifluoroethoxy)pyrimidine-4 -yl)-2,8-diazaspiro[4.5]decane-3-carboxylate is administered daily to a human patient in need thereof for treating pulmonary arterial hypertension.
(Item 23)
(S)-ethyl 8-(2-amino-6-((R)-1-(5-chloro-[1,1'-biphenyl]-2-yl)-2 in an amount effective for a human patient in need thereof) ,2,2-Trifluoroethoxy)pyrimidin-4-yl)-2,8-diazaspiro[4.5]decane-3-carboxylate was administered daily, and urinary 5-HIAA decreased by 50% within 14 days of administration. A method of treating pulmonary arterial hypertension effective to reduce more than
Claims (24)
(S)-ethyl 8-(2-amino-6-((R)-1-(5-chloro-[1,1'-biphenyl]-2-yl) for treating pulmonary arterial hypertension -2,2,2-trifluoroethoxy)pyrimidin-4-yl)-2,8-diazaspiro[4.5]decane-3-carboxylate, wherein said medicament is administered to a human patient in need of said (S)-ethyl 8-(2-amino-6-((R)-1-(5-chloro-[1,1'-biphenyl]-2-yl)-2,2,2-trifluoroethoxy) Pyrimidin-4-yl)-2,8-diazaspiro[4.5]decane-3- carboxylate in an amount effective to reduce urinary 5-HIAA by more than 50% within 14 days after initiation of administration A medicament characterized by daily administration.
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201962798827P | 2019-01-30 | 2019-01-30 | |
US62/798,827 | 2019-01-30 | ||
PCT/IB2020/000074 WO2020157577A1 (en) | 2019-01-30 | 2020-01-30 | A dosage regime and method for treating pulmonary arterial hypertension with rodatristat ethyl |
Publications (2)
Publication Number | Publication Date |
---|---|
JP2022518944A JP2022518944A (en) | 2022-03-17 |
JPWO2020157577A5 true JPWO2020157577A5 (en) | 2022-12-19 |
Family
ID=70285725
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2021544351A Pending JP2022518944A (en) | 2019-01-30 | 2020-01-30 | Dosing regimens and methods for the treatment of pulmonary arterial hypertension |
Country Status (9)
Country | Link |
---|---|
US (2) | US11607413B2 (en) |
EP (1) | EP3917531A1 (en) |
JP (1) | JP2022518944A (en) |
KR (1) | KR20210133953A (en) |
CN (1) | CN113557022A (en) |
AU (1) | AU2020213746A1 (en) |
CA (1) | CA3128327A1 (en) |
MX (1) | MX2021009055A (en) |
WO (1) | WO2020157577A1 (en) |
Families Citing this family (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN113227093A (en) * | 2018-11-14 | 2021-08-06 | 阿尔塔万特科学公司 | Crystalline spiro compounds, dosage forms comprising the compounds, methods for treatment of disease, and methods of recrystallization |
JP2022507533A (en) * | 2018-11-16 | 2022-01-18 | アルタバント・サイエンシズ・ゲーエムベーハー | Treatment of pulmonary arterial hypertension associated with pulmonary arterial hypertension and other diseases |
WO2020157577A1 (en) | 2019-01-30 | 2020-08-06 | Altavant Sciences Gmbh | A dosage regime and method for treating pulmonary arterial hypertension with rodatristat ethyl |
WO2020188352A1 (en) * | 2019-03-15 | 2020-09-24 | Altavant Sciences Gmbh | A method for treating pulmonary arterial hypertension and associated pulmonary arterial hypertension and daily dosing |
WO2023062595A1 (en) | 2021-10-14 | 2023-04-20 | Altavant Sciences Gmbh | Treatment of subjects having pulmonary arterial hypertension with rodatristat ethyl |
Family Cites Families (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
AU2008275179B2 (en) | 2007-07-11 | 2013-09-12 | Lexicon Pharmaceuticals, Inc. | Methods and compositions for treating pulmonary hypertension and related diseases and disorders |
UA119247C2 (en) | 2013-09-06 | 2019-05-27 | РОЙВЕНТ САЙЕНСИЗ ҐмбГ | Spirocyclic compounds as tryptophan hydroxylase inhibitors |
CN113227093A (en) * | 2018-11-14 | 2021-08-06 | 阿尔塔万特科学公司 | Crystalline spiro compounds, dosage forms comprising the compounds, methods for treatment of disease, and methods of recrystallization |
JP2022507533A (en) | 2018-11-16 | 2022-01-18 | アルタバント・サイエンシズ・ゲーエムベーハー | Treatment of pulmonary arterial hypertension associated with pulmonary arterial hypertension and other diseases |
WO2020128608A1 (en) | 2018-12-17 | 2020-06-25 | Altavant Sciences Gmbh | Compound for use in a method for treating sarcoidosis-associated pulmonary hypertension |
WO2020128614A1 (en) | 2018-12-17 | 2020-06-25 | Altavant Sciences Gmbh | Method for treating interstital lung disease |
WO2020157577A1 (en) | 2019-01-30 | 2020-08-06 | Altavant Sciences Gmbh | A dosage regime and method for treating pulmonary arterial hypertension with rodatristat ethyl |
WO2020188352A1 (en) * | 2019-03-15 | 2020-09-24 | Altavant Sciences Gmbh | A method for treating pulmonary arterial hypertension and associated pulmonary arterial hypertension and daily dosing |
-
2020
- 2020-01-30 WO PCT/IB2020/000074 patent/WO2020157577A1/en unknown
- 2020-01-30 MX MX2021009055A patent/MX2021009055A/en unknown
- 2020-01-30 EP EP20718760.0A patent/EP3917531A1/en not_active Withdrawn
- 2020-01-30 US US16/777,458 patent/US11607413B2/en active Active
- 2020-01-30 CA CA3128327A patent/CA3128327A1/en active Pending
- 2020-01-30 AU AU2020213746A patent/AU2020213746A1/en active Pending
- 2020-01-30 JP JP2021544351A patent/JP2022518944A/en active Pending
- 2020-01-30 CN CN202080016400.5A patent/CN113557022A/en active Pending
- 2020-01-30 KR KR1020217024232A patent/KR20210133953A/en unknown
-
2023
- 2023-01-25 US US18/159,494 patent/US20240041877A1/en active Pending
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US9737540B2 (en) | Combination treatment of cancer | |
US4634703A (en) | Method for alleviation of panic disorders | |
KR101900520B1 (en) | A combination composition | |
CZ284928B6 (en) | The use of riluzol or pharmaceutically acceptable salts thereof for preparing medicaments | |
JP2024019691A (en) | Treatment of pulmonary arterial hypertension and pulmonary arterial hypertension associated with other diseases | |
JP2010065060A (en) | Composite treatment for heart failure treatment | |
JP2004525143A5 (en) | ||
JP2022019937A (en) | Composition for preventing or treating chronic or acute virus infection and/or sepsis in humans or animals | |
JPWO2020157577A5 (en) | ||
RU2010109359A (en) | AZITROMYCIN FOR TREATMENT OF SKIN DISEASES | |
JP2001518481A (en) | Serotonin-containing preparations for oral administration and methods of use | |
EP3937928A1 (en) | Capsid assembly modulator solid formulation | |
TW200306185A (en) | Combinations comprising EPOTHILONES and anti-metabolites | |
US20220211708A1 (en) | Pharmaceutical combination of pimozide and methotrexate and use thereof | |
JP2008539265A5 (en) | ||
US20190381034A1 (en) | Pharmaceutical composition and method for acute on chronic liver failure and related liver diseases | |
WO2022122040A1 (en) | Use of bilobalide or ginkgolide composition in preparation of sedative drug | |
JP2012508232A (en) | Hypoestoxide derivatives for the treatment of malaria | |
CN109464441B (en) | Application of 3-acetamido coumarin in preparing medicine for treating or preventing hyperuricemia and kidney injury | |
TW536400B (en) | Pharmaceutical composition for the treatment of immunodeficiency disease which cause by HIV infection | |
JPWO2020188352A5 (en) | ||
AU2005224154A1 (en) | Pharmaceutical composition of (+)-erythro-mefloquine and its use in the treatment of an inflammatory condition | |
US20210220371A1 (en) | Method for smoking cessation | |
CN112007024A (en) | Use of combinations of ereoxib and tramadol for preparing a medicament for treating pain | |
JPS5920221A (en) | Improving and treating agent for raynaud's symptom |